Progyny, Inc. $PGNY Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. increased its stake in Progyny, Inc. (NASDAQ:PGNY) by 2.4% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,106,147 shares of the company’s stock after acquiring an additional 235,513 shares during the quarter. Vanguard Group Inc. owned approximately 0.12% of Progyny worth $217,484,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Ameriprise Financial Inc. increased its stake in shares of Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after purchasing an additional 545,431 shares in the last quarter. Jupiter Asset Management Ltd. acquired a new position in shares of Progyny during the second quarter valued at approximately $10,525,000. Nomura Holdings Inc. purchased a new position in shares of Progyny in the second quarter valued at approximately $9,368,000. Fort Washington Investment Advisors Inc. OH boosted its stake in shares of Progyny by 33.1% in the third quarter. Fort Washington Investment Advisors Inc. OH now owns 1,656,558 shares of the company’s stock worth $35,649,000 after acquiring an additional 412,395 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of Progyny by 57.1% during the third quarter. Principal Financial Group Inc. now owns 704,267 shares of the company’s stock worth $15,156,000 after purchasing an additional 256,078 shares in the last quarter. 94.93% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Q4 results beat consensus on both EPS and revenue (EPS $0.48 vs. $0.38 est.; revenue $318.4M vs. ~$314M est.), showing year-over-year revenue growth. Read More.
• Positive Sentiment: Strong cash generation and shareholder returns: Progyny reported record $210.2M operating cash flow for the year and has repurchased ~6.5M shares under its authorization to date. Read More.
• Positive Sentiment: FY 2026 EPS guidance was raised above consensus (1.83–1.95 vs. ~1.55Street est.), indicating management expects better full‑year profitability despite near‑term revenue headwinds. Read More.
• Neutral Sentiment: Transcripts and slide deck from the earnings call are available for investors who want management detail on drivers (retention, pricing, membership growth) and cadence of benefits. Read More.
• Negative Sentiment: Near‑term revenue guidance disappointed: Q1 2026 revenue guidance ($319M–$332M) is below consensus (~$345M), which likely explains the sell‑off despite the EPS beat and stronger FY EPS outlook. Read More.
• Negative Sentiment: Short interest has risen materially (reported ~41% increase in shares sold short in February to ~4.0M shares, ~5.1% of float), increasing downside pressure and volatility. Read More.

Analyst Ratings Changes

PGNY has been the topic of a number of research reports. Zacks Research lowered Progyny from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Citigroup raised Progyny to an “outperform” rating in a research note on Tuesday, January 20th. Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. KeyCorp boosted their target price on Progyny from $30.00 to $32.00 and gave the stock an “overweight” rating in a research note on Thursday, January 8th. Finally, JPMorgan Chase & Co. set a $35.00 price objective on shares of Progyny in a report on Wednesday, January 21st. Eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $29.20.

Progyny Price Performance

Shares of Progyny stock opened at $17.69 on Monday. Progyny, Inc. has a 1 year low of $16.75 and a 1 year high of $28.75. The business has a 50 day moving average price of $23.90 and a 200 day moving average price of $23.11. The company has a market capitalization of $1.53 billion, a P/E ratio of 27.22, a P/E/G ratio of 1.12 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last released its earnings results on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The firm had revenue of $318.40 million during the quarter, compared to the consensus estimate of $314.26 million. Progyny had a net margin of 4.54% and a return on equity of 11.37%. Progyny’s revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.42 earnings per share. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, research analysts expect that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.